Yes, they may be vaccinated with any FDA-licensed or FDA-authorized updated (2023–2024 Formula) COVID-19 vaccine (Moderna, Pfizer, or Novavax) as long as they do not have a contraindication to vaccination. Antibody testing is not recommended to assess for immunity to SARS-CoV-2 following COVID-19 vaccination.
Recipients should be counseled about the unknown and variable effectiveness of COVID-19 vaccination in immunocompromised populations and the potential for reduced immune responses. They should maintain other practices, such as wearing a mask in public and avoiding crowds, to reduce their risk of exposure to SARS-CoV-2.
The current immunization schedules for each available vaccine product for people age 6 months or older with moderate or severe immunocompromise are shown on CDC’s Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older: www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf.
CDC has also developed an infographic for use with patients who have moderate to severe immunocompromise when determining what updated (2023–2024 Formula) COVID-19 vaccine is due based on the individual’s age and past COVID-19 vaccination history: www.cdc.gov/vaccines/covid-19/downloads/COVID19-vaccination-recommendations-immunocompromised.pdf.
CDC provides detailed considerations for vaccination of people with moderate or severe immunocompromise here: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised.